

Practitioner's Docket No. MBIO99-057CP2M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Samantha J. Busfield et al.
Application No.: 09/503,387 Group: 1644
Filed: February 14, 2000 Examiner: HUYNH, PHUONG N.
For: GLYCOPROTEIN VI AND USES THEREOF

Commissioner for Patents
Washington, D.C. 20231

**REVOCATION OF PRIOR POWERS OF ATTORNEY
AND APPOINTMENT OF NEW POWER OF ATTORNEY**

Dear Sir:

INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE
MEDICALE (INSERM), the Assignee of the entire right, title and interest in the above-identified application by virtue of the Assignment document filed with the United States Patent and Trademark Office on June 1, 2000, at Reel 010868, Frame 0484 hereby revokes all Powers of Attorney with respect to that application heretofore granted and appoints the below listed attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the Patent Office connected therewith.

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

- ☐ deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail.

- ☐ as "Express Mail Post Office to Address"
Mailing Label No.

TRANSMISSION

- ☒ transmitted by facsimile to the Patent and Trademark Office.

Date: 5/20/03

Signature Mary Mackinnon
Mary Mackinnon
(type or print name of person certifying)

*WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

(Page 1 of 2)

Practitioner's Docket No. MBIO99-057CP2M

Scott A. Brown, Reg. No. 32,724; Ian R. Silverman, Reg. No. 37,443; Jean M. Silveri, Reg. No. 39,030; Allan N. Kutzeno, Reg. No. 38,945; Janice M. Klunder, Reg. No. 41,121; Theodore R. Allen, Reg. No. 41,578; Kerri Pollard Schray, Reg. No. 47,066, Tracy M. Sioussat, Reg. No. 50,609; and Paul J. Paglierani, Reg. No. 52,498

all of Millennium Pharmaceuticals, Inc., 75 Sidney Street, Cambridge, Massachusetts 02139, United States of America.

Please direct all future correspondence to:

Intellectual Property Group
MILLENNIUM PHARMACEUTICALS, INC.
75 Sidney Street
Cambridge, MA 02139

and direct all telephone calls to Paul J. Paglierani at 617-761-6865.

INSTITUTE NATIONAL DE LA SANTE ET
DE LA RECHERCHE MEDICALE (INSERM)

By: 

Typed Name: MARTINE JANDROT-ZERRUS

Title: Research Director INSERM

Dated: 04/28/2003

Christine BERLING
Directrice Adjointe
Département Valorisation
et Transfert de Technologies 

Pour le Directeur Général et par délégation
INSERM

INSTITUT NATIONAL de la SANTE
et de la RECHERCHE MEDICALE
101, rue de Tolbiac
75654 PARIS CEDEX 13